Drug Development Pharma - March 24, 2025
New findings about Elypta’s urine test in kidney cancer follow-up
Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.
Business article - March 12, 2025
Boule Diagnostics closes BM950 project and announces new portfolio strategy
Boule Diagnostics announces the decision to close the BM950 project due to newly identified technical issues that have significantly impacted the project’s time to market and overall profitability.
New Market - February 10, 2025
Boule Diagnostics enters distribution agreement
Boule Diagnostics has entered into an exclusive distribution agreement with VitalScientific for the US market.
Financing - January 14, 2025
MONCYTE Health joins EUR 7 million project
MONCYTE Health has been selected to join a 4-year Horizon funded project as a core industrial partner.
Finland - January 10, 2025
Orion and Marinus terminate agreement
Orion Corporation and Marinus Pharmaceuticals have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone.
Business article - August 26, 2024
Attana’s technology applied in malaria vaccine development
In a new publication in “Vaccines” from Department of Immunology and Microbiology, Centre for translational Medicine & Parasitology at Copenhagen University, Attana’s technology has been applied to determine the interaction kinetics between antibodies from vaccinated mice and the pathogen antigen used for the vaccines. This provides valuable information for creating a vaccine with optimal neutralizing […]
